Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity

Summary

Kura Oncology announced publication of ziftomenib characterization in Blood journal, detailing the compound's potency, selectivity, and mechanism of action in preclinical studies.